Sign in

    Oliver Burrow

    registered representative in the UK and is expected to hold relevant professional credentials consistent with equity research roles at Goldman Sachs

    Oliver Burrow is an Equity Research Analyst at Goldman Sachs International, specializing in European healthcare and pharmaceuticals with a particular focus on companies such as Bayer AG. He regularly participates in major industry conferences and is cited as a key presenter in high-level corporate events with C-suite executives from leading firms. Burrow began his career after graduating from University College London, accumulating prior experience at regulatory and investment institutions and becoming part of Goldman Sachs' London-based equity research team by 2022. He is a registered representative in the UK and is expected to hold relevant professional credentials consistent with equity research roles at global investment banks.

    Oliver Burrow's questions to Zealand Pharma A/S/ADR (ZLDPF) leadership

    Oliver Burrow's questions to Zealand Pharma A/S/ADR (ZLDPF) leadership • Q1 2025

    Question

    Oliver Burrow from Goldman Sachs asked for perspective on the amylin competitive landscape, including assets from AbbVie and Lilly, and requested details on the R&D cost-sharing structure of the Roche partnership.

    Answer

    CEO Adam Steensberg described the Roche agreement as a 50-50 R&D cost-share, with Zealand being well-capitalized to fund its obligations. On competition, he positioned petrelintide as a potential best-in-class asset with a strong timeline, viewing Novo Nordisk as the main competitor. He characterized Lilly's asset as lacking clinical data and the AbbVie/Gubra program as being years behind with inconsistent data.

    Ask Fintool Equity Research AI